Preferred Label : complement C1 inhibitor protein;
MeSH definition : An endogenous 105-kDa plasma glycoprotein produced primarily by the LIVER and MONOCYTES.
It inhibits a broad spectrum of proteases, including the COMPLEMENT C1R and the COMPLEMENT
C1S proteases of the CLASSICAL COMPLEMENT PATHWAY, and the MANNOSE-BINDING PROTEIN-ASSOCIATED
SERINE PROTEASES. C1-INH-deficient individuals suffer from HEREDITARY ANGIOEDEMA TYPES
I AND II.;
MeSH synonym : c1 inh protein; c1-inhibitor protein; c1-inh protein; plasma protease c1 inhibitor; c1 inhibitor protein; Serpin G1; c1 esterase inhibitor; esterase inhibitor, c1; complement C1-Inhibitor protein; Serpin Family G Member 1; SERPING1;
CISMeF synonym : protein, c1-inh; inhibitor, c1 esterase; protein, c1-inhibitor; protein, complement c1-inhibitor; G1, Serpin;
MeSH annotation : do not confuse with COMPLEMENT C1 INACTIVATOR PROTEINS;
Is substance : O;
Origin ID : D050718;
UMLS CUI : C0540301;
ATC code(s)
Allowable qualifiers
Currated CISMeF NLP mapping
Pharmacological action(s)
Record concept(s)
Related MeSH Supplementary Concept(s)
Related MeSH term(s)
See also
Semantic type(s)
Validated automatic mappings to BTNT
An endogenous 105-kDa plasma glycoprotein produced primarily by the LIVER and MONOCYTES.
It inhibits a broad spectrum of proteases, including the COMPLEMENT C1R and the COMPLEMENT
C1S proteases of the CLASSICAL COMPLEMENT PATHWAY, and the MANNOSE-BINDING PROTEIN-ASSOCIATED
SERINE PROTEASES. C1-INH-deficient individuals suffer from HEREDITARY ANGIOEDEMA TYPES
I AND II.
https://ansm.sante.fr/tableau-acces-derogatoire/berinert-500-ui-mg-poudre-et-solvant-pour-solution-injectable-perfusion
2024
false
false
false
France
French
complement C1 inhibitor protein
guidelines for drug use
continuity of patient care
salvage therapy
graft rejection
Humoral rejection
heart transplantation
kidney transplantation
lung transplantation
infusions, intravenous
complement C1 inhibitor protein
technical report
---
https://www.has-sante.fr/jcms/p_3258709/fr/ruconest
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
conestat alfa
child
adolescent
adult
angioedemas, hereditary
Hereditary angioedema attack
complement inactivating agents
evaluation of the transparency committee
conestat alfa
complement C1 inhibitor protein
recombinant proteins
---
https://www.has-sante.fr/portail/jcms/c_2905739/fr/ruconest
2019
false
false
false
France
conestat alfa
conestat alfa
evaluation of the transparency committee
complement C1 inhibitor protein
recombinant proteins
---
https://www.has-sante.fr/portail/jcms/c_2873713/fr/ruconest
2018
false
France
English
French
evaluation of the transparency committee
adolescent
acute disease
angioedemas, hereditary
complement inactivating agents
orphan drug production
injections, intravenous
treatment outcome
conestat alfa
complement C1 inhibitor protein
complement C1 inhibitor protein
recombinant proteins
conestat alfa
---
https://www.has-sante.fr/portail/jcms/c_2873722/fr/ruconest
https://www.has-sante.fr/portail/jcms/c_2873722/fr/ruconest-conestat-alpha-medicaments-de-l-angioedeme-hereditaire
2018
false
false
false
France
conestat alfa
treatment outcome
conestat alfa
guidelines for drug use
angioedemas, hereditary
injections, intravenous
adult
evaluation of the transparency committee
complement C1 inhibitor protein
recombinant proteins
---
https://www.has-sante.fr/portail/jcms/c_2873701/fr/cinryze
https://www.has-sante.fr/portail/jcms/c_2873701/fr/cinryze-inhibiteur-de-la-c1-esterase-humaine
2018
false
false
false
false
France
French
evaluation of the transparency committee
C1-inhibitor, plasma derived
SERPING1 protein, human
guidelines for drug use
injections, intravenous
treatment outcome
angioedemas, hereditary
angioedema
angioedema
adult
adolescent
complement c1 inactivator proteins
complement C1 inhibitor protein
---
https://www.has-sante.fr/portail/jcms/c_2873719/fr/berinert
https://www.has-sante.fr/portail/jcms/c_2873719/fr/berinert-inhibiteur-de-la-c1-esterase-humaine
2018
false
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
SERPING1 protein, human
C1-inhibitor, plasma derived
treatment outcome
hereditary angioedema types I and II
hereditary angioedema types I and II
infusions, intravenous
adult
child
complement c1 inactivator proteins
complement C1 inhibitor protein
---
https://www.ansm.sante.fr/actualites/recommandations-dutilisation-des-inhibiteurs-de-la-c1-esterase-humaine-cinryze-et-berinert-en-periode-de-tensions-dapprovisionnement
2018
false
false
false
France
French
pharmacovigilance note
guidelines for drug use
SERPING1 protein, human
SERPING1 protein, human
injections, intravenous
infusions, intravenous
angioedemas, hereditary
angioedemas, hereditary
pregnancy
child
C1-inhibitor, plasma derived
SERPING1 protein, human
injections, subcutaneous
algorithms
icatibant
conestat alfa
recombinant proteins
conestat alfa
complement C1 inhibitor protein
complement C1 inhibitor protein
complement C1 inhibitor protein
icatibant
danazol
dexchlorpheniramine
histamine h1 antagonists
epinephrine
adult
complement c1 inactivator proteins
complement c1 inactivator proteins
complement c1 inactivator proteins
bradykinin
bradykinin
chlorpheniramine
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=64075802
2012
France
summary of product characteristics
package leaflet
humans
SERPING1 protein, human
powders
injections
SERPING1 protein, human
complement C1 inhibitor protein
---
https://www.ema.europa.eu/medicines/human/EPAR/Cinryze
2012
United Kingdom
English
French
summary of product characteristics
drug evaluation
package leaflet
syndication feed
complement C1 inhibitor protein
complement C1 inhibitor protein
drug approval
treatment outcome
adult
adolescent
angioedemas, hereditary
injections, intravenous
C1-inhibitor, plasma derived
pregnancy
breast feeding
drug evaluation, preclinical
complement c1 inactivator proteins
complement c1 inactivator proteins
SERPING1 protein, human
SERPING1 protein, human
---
http://amsao.free.fr/
France
French
complement C1 inhibitor protein
hereditary angioedema types I and II
association of patients
---
http://www.has-sante.fr/portail/jcms/c_1264432/cinryze
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-07/cinryze_20062012_avis_ct12045.pdf
2012
France
French
secondary prevention
evaluation of the transparency committee
complement c1 inactivator proteins
SERPING1 protein, human
C1-inhibitor, plasma derived
angioedemas, hereditary
angioedema
adult
adolescent
complement C1 inhibitor protein
aged
injections, intravenous
treatment outcome
clinical trials, phase iii as topic
angioedema
complement inactivating agents
orphan drug production
---
https://www.ema.europa.eu/medicines/human/EPAR/Ruconest
2011
false
United Kingdom
English
French
syndication feed
drug approval
adult
angioedemas, hereditary
treatment outcome
injections, intravenous
recombinant proteins
recombinant proteins
aged
pregnancy
drug evaluation, preclinical
conestat alfa
package leaflet
drug evaluation
summary of product characteristics
complement C1 inhibitor protein
complement C1 inhibitor protein
conestat alfa
conestat alfa
---
http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-04/ruconest_-_ct-9842.pdf
http://www.has-sante.fr/portail/jcms/c_1061981/ruconest-conestat-alpha-analogue-de-linhibiteur-de-la-c1-esterase-humaine-synthese-d-avis
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-11/ruconest_ct_9842.pdf
2011
France
English
French
evaluation of the transparency committee
guidelines for drug use
angioedemas, hereditary
complement inactivating agents
orphan drug production
adult
injections, intravenous
treatment outcome
conestat alfa
complement C1 inhibitor protein
complement C1 inhibitor protein
recombinant proteins
conestat alfa
---
http://www.has-sante.fr/portail/jcms/c_870428/berinert-inhibiteur-de-la-c1-esterase-humaine-c1-inh
http://www.has-sante.fr/portail/jcms/c_827809/berinert-ct-6744
http://www.has-sante.fr/portail/jcms/c_870427/synthese-d-avis-berinert-ct-6744
2009
France
French
orphan drug production
complement C1 inhibitor protein
hereditary angioedema types I and II
complement inactivating agents
treatment outcome
injections, intravenous
infusions, intravenous
C1-inhibitor, plasma derived
complement c1 inactivator proteins
SERPING1 protein, human
evaluation of the transparency committee
guidelines for drug use
---